Interpreting Key Trials

Abciximab prevents ischemic complications during angioplasty

The EPILOG Trial

Author and Disclosure Information


The EPILOG trial showed that the platelet glycoprotein IIb/IIIa inhibitor abciximab, together with heparin in a low, weight-adjusted dose, markedly reduced the risk of acute ischemic complications during percutaneous coronary revascularization, without increasing the risk of hemorrhage.


Next Article: